The world's first "Made in Chengdu" breakthrough anti-cancer drug approved for market.

On June 22, according to the official website of the National Medical Products Administration, the EGFRHER3 dual antibody ADC drug Lunconyiqingtuo monoclonal antibody, independently developed by Chengdu pharmaceutical company Baili Tianheng, has officially been approved for marketing. It is used to treat adult patients with recurrent/metastatic nasopharyngeal cancer who have previously failed at least second-line systemic chemotherapy and PD-1/PD-L1 inhibitor therapy.